Table 1.
Clinical trials in treatment of solid tumors in China by CAR-T cells
| Antigen | Tumor target | Sponsor | Phase | NCT number | Study start |
|---|---|---|---|---|---|
| CD133 | Liver cancer; pancreatic cancer; brain tumor; breast cancer; ovarian tumor; colorectal cancer, acute myeloid lymphoid leukemias | Chinese PLA General Hospital | Phase 1 | NCT02541370 | 2015 |
| CD138 | Multiple myeloma | Chinese PLA General Hospital | Phase 1/Phase 2 | NCT01886976 | 2013 |
| CD19 | Recurrent or refractory B-cell tumor | Second Military Medical University | Phase 1/Phase 2 | NCT02644655 | 2015 |
| CEA | Lung cancer; colorectal cancer; gastriccancer; breast cancer; pancreatic cancer | Southwest Hospital | Phase 1 | NCT02349724 | 2014 |
| Claudin 18.2 | Advanced gastric adenocarcinoma, pancreatic adenocarcinoma | Changhai Hospital | NA | NCT03159819 | 2017 |
| EGFR | Advanced EGFR-positive solid tumors | Chinese PLA General Hospital | Phase 1/Phase 2 | NCT01869166 | 2013 |
| EGFR | Advanced glioma | RenJi Hospital | Phase 1 | NCT02331693 | 2014 |
| EGFR | Advanced solid tumor | Shanghai Cell Therapy Research Institute | Phase 1/Phase 2 | NCT03182816 | 2017 |
| EGFR | EGFR-positive colorectal cancer | Shenzheng Second People's Hospital | Phase 1/Phase 2 | NCT03152435 | 2017 |
| EGFRvIII | Recurrent glioblastoma multiforme | Beijing Sanbo Brain Hospital | Phase 1 | NCT02844062 | 2016 |
| EGFRvIII | Glioblastoma multiforme | Shenzhen Geno-Immune Medical Institute | Phase 1/Phase 2 | NCT03170141 | 2017 |
| EphA2 | EphA2-positive malignant glioma | Fuda Cancer Hospital | Phase 1/Phase 2 | NCT02575261 | 2015 |
| EpCAM | Liver neoplasms | Sinobioway Cell Therapy Co., Ltd. | NA | NCT02729493 | 2015 |
| EpCAM | Stomach neoplasms | Sinobioway Cell Therapy Co., Ltd. | NA | NCT02725125 | 2015 |
| EpCAM | Malignant neoplasms of the nasopharynx, TNM staging, distant metastasis and breast cancer recurrence | Sichuan University | Phase 1 | NCT02915445 | 2016 |
| EpCAM | Colon cancer, esophageal carcinoma, pancreatic cancer, prostate cancer, gastric cancer, hepatic carcinoma | First Affiliated Hospital of Chengdu Medical College | Phase 1/Phase 2 | NCT03013712 | 2017 |
| GD2 | Neuroblastoma | Zhujiang Hospital | Phase 2 | NCT02765243 | 2016 |
| GD2 | Relapsed or refractory neuroblastoma | Sinobioway Cell Therapy Co., Ltd. | NA | NCT02919046 | 2016 |
| GD2 | Solid tumor | Shenzhen Geno-Immune Medical Institute | Phase 1/Phase 2 | NCT02992210 | 2016 |
| GPC3 | Hepatocellular carcinoma | RenJi Hospital | Phase 1 | NCT02395250 | 2015 |
| GPC3 | Hepatocellular carcinoma and liver metastases | Shanghai GeneChem Co., Ltd. | Phase 1/Phase 2 | NCT02715362 | 2016 |
| GPC3 | GPC3-positive hepatocellular carcinoma | Funda Cancer Hospital, Guangzhou | Phase 1/Phase 2 | NCT02723942 | 2015 |
| GPC3 | Lung squamous cell carcinoma | Carsgen Therapeutics, Ltd. | Phase 1 | NCT02876978 | 2016 |
| GPC3 | Hepatocellular carcinoma | Shanghai GeneChem Co., Ltd. | Phase 1/Phase 2 | NCT03130712 | 2017 |
| GPC3 | Advanced hepatocellular carcinoma | Xinqiao Hospital of Chongqing | Phase 1/Phase 2 | NCT03084380 | 2017 |
| GPC3 | Hepatocellular carcinoma, squamous cell lung cancer | Second Affiliated Hospital of Chengdu Medical University | Phase 1 | NCT03198546 | 2017 |
| GPC3 | Hepatocellular carcinoma | RenJi Hospital | - | NCT03146234 | 2017 |
| GPC3/MSLN/ CEA | Hepatocellular, pancreatic cancer, colorectal cancer | Shanghai GeneChem Co., Ltd. | Phase 1/Phase 2 | NCT02959151 | 2016 |
| HER2 | Tumors refractory to chemotherapy and/or HER2 antibody therapy, advanced HER2-positive solid tumors | Chinese PLA General Hospital | Phase 1/Phase 2 | NCT01935843 | 2013 |
| HER2 | Breast cancer, ovarian cancer, lung cancer, gastric cancer, colorectal cancer, glioma, pancreatic caner | Southwest Hospital | Phase 1/Phase 2 | NCT02713984 | 2016 |
| HER2 | Breast cancer | Fudan Cancer Hospital | Phase 1/Phase 2 | NCT02547961 | 2015 |
| HerinCAR-PD1 | Advanced malignancies | Ningbo Cancer Hospital | Phase 1/Phase 2 | NCT02873390 | 2016 |
| HerinCAR-PD1 | Advanced solid tumors (lung, liver, and stomach) | Shanghai International Medical Center | Phase 1/Phase 2 | NCT02862028 | 2016 |
| MSLN | Malignant mesothelioma, pancreatic cancer; ovarian tumor; triple negative breast cancer; endometrial cancer; other mesothelin-positive tumors | Chinese PLA General Hospital | Phase 1 | NCT02580747 | 2015 |
| MSLN | Pancreatic cancer | Shanghai GeneChem Co., Ltd. | Phase 1 | NCT02706782 | 2016 |
| MSLN | Mesothelin-positive tumors | China Meitan General Hospital | Phase 1 | NCT02930993 | 2016 |
| MSLN | Solid tumors, adult advanced cancer | Ningbo Cancer Hospital | Phase 1/Phase 2 | NCT03030001 | 2017 |
| MSLN | Advanced solid tumors | Shanghai Cell Therapy Research Institute | Phase 1/Phase 2 | NCT03182803 | 2017 |
| MG7 | Liver metastases | Xijing Hospital | Phase 1/Phase 2 | NCT02862704 | 2016 |
| MUC1 | Malignant glioma of the brain; colorectal carcinoma; gastric carcinoma | PersonGen Biomedicine (Suzhou) Co., Ltd. | Phase 1/Phase 2 | NCT02617134 | 2015 |
| MUC1 | Advanced refractory solid tumors (hepatocellular carcinoma, NSCLC, pancreatic carcinoma, triple-negative invasive breast carcinoma) | PersonGen Biomedicine (Suzhou) Co., Ltd. | Phase 1/Phase 2 | NCT02587689 | 2015 |
| MUC1 | Advanced solid tumors | Shanghai Cell Therapy Research Institute | Phase 1/Phase 2 | NCT03179007 | 2017 |
| NY-ESO-1 | Advanced NSCLC | Guangzhou Institute of Respiratory Disease | Phase 1 | NCT03029273 | 2017 |
| LMP1 | Nasopharyngeal neoplasms | The Second Hospital of Nanjing Medical University | Phase 1/Phase 2 | NCT02980315 | 2016 |
| PD-L1 CSR | Glioblastoma multiforme | Beijing Sanbo Brain Hospital | Phase 1 | NCT02937844 | 2016 |
| PSCA/MUC1/ PD-L1/CD80/86 | Advanced lung or other cancers | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 | NCT03198052 | 2017 |
| PSMA/FRα | Bladder cancer, urothelial carcinoma bladder | Shenzhen Geno-Immune Medical Institute | Phase 1/Phase 2 | NCT03185468 | 2017 |
| Zeushield | NSCLC | Second Xiangya Hospital of Central South University | Phase 1 | NCT03060343 | 2016 |
*The clinical trials are collected from clinicaltrials.gov